POP-OUT | CLOSE

An Information Portal to 105097 Biological Macromolecular Structures

 
[6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE
 
AQ4 is found in 2 entries
AQ4
  •   Chemical Component Summary   Hide
    Name [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE
    Identifiers N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
    Synonyms ERLOTINIB
    Formula C22 H23 N3 O4
    Molecular Weight 393.44 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key AAKJLRGGTJKAMG-UHFFFAOYSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00530   (Stereoisomeric match)
    Name Erlotinib
    Groups
    • approved
    • investigational
    Description Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
    Synonyms
    • [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
    • Erlotinib
    • OSI-774
    Salts Erlotinib Hydrochloride
    Brand names Tarceva
    Affected organism Humans and other mammals
    Indication For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
    Mechanism of action The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.
    Route of administration Oral
    Categories Protein Kinase Inhibitors
    ATC-Code L01XE03
    AHFS-Code 10:00.00
    CAS number 183321-74-6
    Targets
    Name Sequence search Pharmacological action Actions
    Epidermal growth factor receptor   Search  yes antagonist
    Nuclear receptor subfamily 1 group I member 2   Search  yes agonist
     
Ligand Image